Microvesicles analysis

PreclinicalBiologic

AAzienda Ospedaliero-Universitaria di Parma

Microvesicles analysis is one of 45 biologic programs targeting Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

11 2

Idamycin

Pfizer

Phase 3

10 3

Oncovin

Eli Lilly

Phase 3

9 4

Neoral

Novartis

Phase 3

9 5

Novantrone

Pfizer

Phase 3

8 6

Leukine

Sanofi

Phase 3

7 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

15 8

Rayos

RRoxane Laboratories

Phase 3

14 9

Busulfex

Akero Therapeutics

Phase 3

13 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leukemia1 trial

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting·AAzienda Ospedaliero-Universitaria di Parma·N/A·NCT06626893·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microvesicles analysis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microvesicles analysis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microvesicles analysis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliero-Universitaria di Parma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAzienda Ospedaliero-Universitaria di Parma

Microvesicles analysis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leukemia1 trial

References

Drug Info

Quick Facts

Related News